Cargando…

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

BACKGROUND: Patients with atherosclerotic cardiovascular disease who require additional low-density lipoprotein cholesterol (LDL-C) lowering despite maximally tolerated statins have a significant unmet medical need and are at increased risk of future cardiovascular events and a reduced quality of li...

Descripción completa

Detalles Bibliográficos
Autores principales:	McQueen, R. Brett, Baum, Seth J., Louie, Michael J., Sasiela, William J., Bilitou, Aikaterini, Shah, Hemal, Nash, Beth, Gillard, Kristin K., Ray, Kausik K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845167/ https://www.ncbi.nlm.nih.gov/pubmed/36316612 http://dx.doi.org/10.1007/s40256-022-00552-7

Ejemplares similares

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
por: Bays, Harold E., et al.
Publicado: (2021)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

THU584 Comparison Of The Cardiovascular Benefits Of Bempedoic Acid With Statins- Analysis By The Cholesterol Treatment Trialists’ Methodology
por: Lincoff, A Michael, et al.
Publicado: (2023)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks
por: Kao, Yu-Cheng, et al.
Publicado: (2021)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients
por: Toplak, Hermann, et al.
Publicado: (2023)

Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
por: Gunn, Laura H., et al.
Publicado: (2022)

Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
por: Pradhan, Akshyaya, et al.
Publicado: (2020)

Combination therapy in cholesterol reduction: focus on ezetimibe and statins
por: Grigore, Liliana, et al.
Publicado: (2008)

The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
por: NODARI, SAVINA, et al.
Publicado: (2007)

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
por: Hamilton-Craig, Ian, et al.
Publicado: (2010)

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
por: Shaya, Fadia Tohme, et al.
Publicado: (2019)

The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis
por: Zhu, Yunyun, et al.
Publicado: (2020)

Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe
por: Choi, Young Hwan, et al.
Publicado: (2014)

Adding ezetimibe to statin therapy: latest evidence and clinical implications
por: Vavlukis, Marija, et al.
Publicado: (2018)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
por: Wan, Shuling, et al.
Publicado: (2021)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk
por: Katzmann, Julius L., et al.
Publicado: (2022)

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers
por: Wu, Na-Qiong, et al.
Publicado: (2018)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality
por: Patel, Akshar Y., et al.
Publicado: (2013)

Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors
por: Brahmachari, Ballari, et al.
Publicado: (2015)

Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe
por: Rea, Federico, et al.
Publicado: (2021)

Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom
por: Reynolds, Timothy Mark, et al.
Publicado: (2021)

Meta-analysis and trial sequential analysis of ezetimibe for coronary atherosclerotic plaque compositions
por: Chai, Bofeng, et al.
Publicado: (2023)

Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis
por: Hong, Namki, et al.
Publicado: (2018)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Synthesis and Modeling of Ezetimibe Analogues
por: Salgado, Mateo M., et al.
Publicado: (2021)

Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV
por: Bennett, Matthew T, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_o101usfkhoah1050c4464rbqvt